Device Recall Poly Component Trial, UCCS

  • 모델명 / 제조번호(시리얼번호)
    Lot Numbers: a) REF 90-SRK-170310, TU53733-01 b) REF 90-SRK-170312, TU53736-01 c) REF 90-SRK-170314, TU53737-01 d) REF 90-SRK-170410, TU53733-02 e) REF 90-SRK-170412, TU53736-02 f) REF 90-SRK-170414, TU53737-02 g) REF 90-SRK-170510, TU53733-03 h) REF 90-SRK-170512, TU53736-03 i) REF 90-SRK-170514, TU53737-03 j) REF 90-SRK-170610, TU53733-04 k) REF 90-SRK-170612, TU53736-04 l) REF 90-SRK-170614, TU53737-04
  • 의료기기 분류등급
  • 의료기기 등급
    2
  • 이식된 장치?
    Yes
  • 유통
    US distribution to AR, MA
  • 제품 설명
    Poly Component Trial, UCCS, packaged in the following sizes and configurations: || a) Poly Comp Trial - UCCS 3x10, REF 90-SRK-170310 || b) Poly Comp Trial - UCCS 3x12, REF 90-SRK-170312 || c) Poly Comp Trial - UCCS 3x14, REF 90-SRK-170314 || d) Poly Comp Trial - UCCS 4x10, REF 90-SRK-170410 || e) Poly Comp Trial - UCCS 4x12, REF 90-SRK-170412 || f) Poly Comp Trial - UCCS 4x14, REF 90-SRK-170414 || g) Poly Comp Trial - UCCS 5x10, REF 90-SRK-170510 || h) Poly Comp Trial - UCCS 5x12, REF 90-SRK-170512 || i) Poly Comp Trial - UCCS 5x14, REF 90-SRK-170514 || j) Poly Comp Trial - UCCS 6x10, REF 90-SRK-170610 || k) Poly Comp Trial - UCCS 6x12, REF 90-SRK-170612 || l) Poly Comp Trial - UCCS 6x14, REF 90-SRK-170614 || The Responsive Orthopedics (RO) Total Knee Arthroplasty (TKA) System is intended to restore alignment, stability, range of motion, and alleviate pain by replacing the articulating surfaces of the knee joint
  • Manufacturer
  • 1 Event

제조사

  • 제조사 주소
    Medtronic Sofamor Danek USA Inc, 1800 Pyramid Pl, Memphis TN 38132-1703
  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    USFDA